GlassScriptPhysician profile
Arpan Satsangi
NPI 1861927931
$14,066.29
in general payments reported to CMS, 2019-2025
19 companies · $2,816 in 2025
The $2,816 reported for 2025 was more than what 86% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $8,098 · 2023: $1,361 · 2024: $1,791 · 2025: $2,816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,063 · Travel and Lodging: $2,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,062.97 |
| Travel and Lodging | $2,904.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $4,818.50 | 2022-2025 | Titan |
| Teleflex LLC | $3,401.12 | 2022-2025 | Urolift, Barrigel |
| Boston Scientific Corporation | $3,063.24 | 2022-2025 | Ams 700 |
| Medtronic, INC. | $1,133.99 | 2022-2024 | Interstim |
| Profound Medical Corp. | $382.70 | 2025 | Tulsa-Pro |
| Procept Biorobotics Corporation | $231.49 | 2024 | Aquabeam System |
| Axonics, INC. | $194.05 | 2022-2024 | Axonics, Bulkamid |
| Smith+Nephew, INC. | $135.62 | 2025 | Stravix Pl, Stravix, Grafix Pl |
| Ars Pharmaceuticals Operations, INC. | $124.06 | 2025 | Neffy |
| Urovant Sciences INC | $109.37 | 2022 | |
| Telix Pharmaceuticals | $107.85 | 2024-2025 | Illuccix |
| Glaxosmithkline, LLC. | $107.82 | 2025 | Shingrix |
| Sumitomo Pharma America, INC. | $81.98 | 2024-2025 | Orgovyx |
| Antares Pharma, INC. | $50.00 | 2023 | Xyosted, Tlando |
| Biotissue Holdings INC. | $34.70 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abc Home Medical Supply, INC. | $26.54 | 2025 | |
| Laborie Medical Technologies Corp. | $25.55 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $24.01 | 2025 | Aptra |
| Pacira Pharmaceuticals Incorporated | $13.70 | 2025 | Exparel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arpan Satsangi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.